Cancer Research Audrey Hepburn Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Park, D. J.
Right arrow Articles by Lenz, H.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Park, D. J.
Right arrow Articles by Lenz, H.-J.
[Cancer Research 61, 8654-8658, December 15, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

A Xeroderma Pigmentosum Group D Gene Polymorphism Predicts Clinical Outcome to Platinum-based Chemotherapy in Patients with Advanced Colorectal Cancer1

David J. Park2, Jan Stoehlmacher2, Wu Zhang, Denice D. Tsao-Wei, Susan Groshen and Heinz-Josef Lenz3

Los Angeles County/University of Southern California Medical Center, Department of Medicine, Los Angeles, California 90033 [D. J. P.], and University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California 90033 [J. S., W. Z., D. D. T-W., S. G., H-J. L.]

The Xeroderma pigmentosum group D (XPD) protein is an essential participant in nucleotide excision repair and basal transcription. There is evidence that three common polymorphisms of the XPD gene (C156A, Asp312Asn, and Lys751Gln) may be associated with differential DNA repair activity. Because increased DNA repair plays an important role in chemoresistance to platinum-based compounds, we assessed the aforementioned polymorphisms in 73 patients with metastatic colorectal cancer and determined their outcome to 5-fluorouracil/oxaliplatin. Among those tested for the Lys751Gln polymorphism, 24% (5 of 21) patients with the Lys/Lys genotype responded, versus 10% (4 of 39) and 10% (1 of 10) of those with the Lys/Gln and Gln/Gln genotypes (P = 0.015). The median survival for those with the Lys/Lys genotype was 17.4 (95% CI 7.9, 26.5) versus 12.8 (95% CI 8.5, 25.9) and 3.3 (95% CI 1.4, 6.5) months for patients with the Lys/Gln and Gln/Gln respectively (P = 0.002). The polymorphisms C156A and Asp312Asn of the XPD gene were not associated with response to 5-fluorouracil/oxaliplatin nor with survival. However, a linkage was observed between the Lys751 allele and the C156 allele (P = 0.028), and between the Lys751Lys genotype and the Asp312Asp genotype (P < 0.001). We conclude that XPD Lys751Gln polymorphism may be an important marker in the prediction of clinical outcome to platinum-based chemotherapy.




This article has been cited by other articles:


Home page
 JCOHome page
E. Goekkurt, S.-E. Al-Batran, J. T. Hartmann, U. Mogck, G. Schuch, M. Kramer, E. Jaeger, C. Bokemeyer, G. Ehninger, and J. Stoehlmacher
Pharmacogenetic Analyses of a Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma With Fluorouracil and Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
J. Clin. Oncol., June 10, 2009; 27(17): 2863 - 2873.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Wu, W. Zhang, R. Qiao, D. Chen, H. Wang, Y. Wang, S. Zhang, G. Gao, A. Gu, J. Shen, et al.
Association of XPD Polymorphisms with Severe Toxicity in Non-Small Cell Lung Cancer Patients in a Chinese Population
Clin. Cancer Res., June 1, 2009; 15(11): 3889 - 3895.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. S. Braun, S. D. Richman, P. Quirke, C. Daly, J. W. Adlard, F. Elliott, J. H. Barrett, P. Selby, A. M. Meade, R. J. Stephens, et al.
Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial
J. Clin. Oncol., June 1, 2008; 26(16): 2690 - 2698.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Gao, D. K. Price, T. Sissung, E. Reed, and W. D. Figg
Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1
Mol. Cancer Ther., May 1, 2008; 7(5): 1246 - 1250.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Tibaldi, E. Giovannetti, E. Vasile, V. Mey, A. C. Laan, S. Nannizzi, R. Di Marsico, A. Antonuzzo, C. Orlandini, S. Ricciardi, et al.
Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients
Clin. Cancer Res., March 15, 2008; 14(6): 1797 - 1803.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Marsh, J. Paul, C. R. King, G. Gifford, H. L. McLeod, and R. Brown
Pharmacogenetic Assessment of Toxicity and Outcome After Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian Cancer
J. Clin. Oncol., October 10, 2007; 25(29): 4528 - 4535.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W.-S. Wang, P.-M. Chen, T.-J. Chiou, J.-H. Liu, J.-K. Lin, T.-C. Lin, H.-S. Wang, and Y. Su
Epidermal Growth Factor Receptor R497K Polymorphism Is a Favorable Prognostic Factor for Patients with Colorectal Carcinoma
Clin. Cancer Res., June 15, 2007; 13(12): 3597 - 3604.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Kuptsova, K. J. Kopecky, J. Godwin, J. Anderson, A. Hoque, C. L. Willman, M. L. Slovak, and C. B. Ambrosone
Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials
Blood, May 1, 2007; 109(9): 3936 - 3944.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Ruzzo, F. Graziano, F. Loupakis, E. Rulli, E. Canestrari, D. Santini, V. Catalano, R. Ficarelli, P. Maltese, R. Bisonni, et al.
Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy
J. Clin. Oncol., April 1, 2007; 25(10): 1247 - 1254.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
T. van der Straaten, D. Kweekel, M. Tiller, J. Bogaartz, and H.-J. Guchelaar
Multiplex Pyrosequencing of Two Polymorphisms in DNA Repair Gene XRCC1
J. Mol. Diagn., September 1, 2006; 8(4): 444 - 448.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Ruzzo, F. Graziano, K. Kawakami, G. Watanabe, D. Santini, V. Catalano, R. Bisonni, E. Canestrari, R. Ficarelli, E. T. Menichetti, et al.
Pharmacogenetic Profiling and Clinical Outcome of Patients With Advanced Gastric Cancer Treated With Palliative Chemotherapy
J. Clin. Oncol., April 20, 2006; 24(12): 1883 - 1891.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Li, M. Frazier, D. B. Evans, K. R. Hess, C. H. Crane, L. Jiao, and J. L. Abbruzzese
Single Nucleotide Polymorphisms of RecQ1, RAD54L, and ATM Genes Are Associated With Reduced Survival of Pancreatic Cancer
J. Clin. Oncol., April 10, 2006; 24(11): 1720 - 1728.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. Moreno, F. Gemignani, S. Landi, L. Gioia-Patricola, A. Chabrier, I. Blanco, S. Gonzalez, E. Guino, G. Capella, F. Canzian, et al.
Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer.
Clin. Cancer Res., April 1, 2006; 12(7): 2101 - 2108.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Li, H. Liu, L. Jiao, D. Z. Chang, G. Beinart, R. A. Wolff, D. B. Evans, M. M. Hassan, and J. L. Abbruzzese
Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival.
Cancer Res., March 15, 2006; 66(6): 3323 - 3330.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. Zienolddiny, D. Campa, H. Lind, D. Ryberg, V. Skaug, L. Stangeland, D. H. Phillips, F. Canzian, and A. Haugen
Polymorphisms of DNA repair genes and risk of non-small cell lung cancer
Carcinogenesis, March 1, 2006; 27(3): 560 - 567.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. A. Mehta, T. A. Alonzo, R. B. Gerbing, J. S. Elliott, T. A. Wilke, R. J. Kennedy, J. A. Ross, J. P. Perentesis, B. J. Lange, and S. M. Davies
XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report
Blood, January 1, 2006; 107(1): 39 - 45.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. L. Allen and P. G. Johnston
Role of Genomic Markers in Colorectal Cancer Treatment
J. Clin. Oncol., July 10, 2005; 23(20): 4545 - 4552.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Yu, W. D. Shannon, M. A. Watson, and H. L. McLeod
Gene Expression Profiling of the Irinotecan Pathway in Colorectal Cancer
Clin. Cancer Res., March 1, 2005; 11(5): 2053 - 2062.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Liu, S. J. O'Day, D. Yang, P. Boasberg, R. Milford, T. Kristedja, S. Groshen, and J. Weber
Impact of Gene Polymorphisms on Clinical Outcome for Stage IV Melanoma Patients Treated with Biochemotherapy: An Exploratory Study
Clin. Cancer Res., February 1, 2005; 11(3): 1237 - 1246.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. M. Allan, A. G. Smith, K. Wheatley, R. K. Hills, L. B. Travis, D. A. Hill, D. M. Swirsky, G. J. Morgan, and C. P. Wild
Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy
Blood, December 15, 2004; 104(13): 3872 - 3877.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Berwick, G. Matullo, Y. S. Song, S. Guarrera, G. Dominguez, I. Orlow, M. Walker, and P. Vineis
Association Between Aryl Hydrocarbon Receptor Genotype and Survival in Soft Tissue Sarcoma
J. Clin. Oncol., October 1, 2004; 22(19): 3997 - 4001.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Isla, C. Sarries, R. Rosell, G. Alonso, M. Domine, M. Taron, G. Lopez-Vivanco, C. Camps, M. Botia, L. Nunez, et al.
Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer
Ann. Onc., August 1, 2004; 15(8): 1194 - 1203.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Chan and D. J. Kerr
Can we individualise chemotherapy for colorectal cancer?
Ann. Onc., July 1, 2004; 15(7): 996 - 999.
[Full Text] [PDF]

Home page
 JCOHome page
H.-J. Lenz
The Use and Development of Germline Polymorphisms in Clinical Oncology
J. Clin. Oncol., July 1, 2004; 22(13): 2519 - 2521.
[Full Text] [PDF]

Home page
 JCOHome page
S. Gurubhagavatula, G. Liu, S. Park, W. Zhou, L. Su, J. C. Wain, T. J. Lynch, D. S. Neuberg, and D. C. Christiani
XPD and XRCC1 Genetic Polymorphisms Are Prognostic Factors in Advanced Non--Small-Cell Lung Cancer Patients Treated With Platinum Chemotherapy
J. Clin. Oncol., July 1, 2004; 22(13): 2594 - 2601.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
M. P. Goetz, M. M. Ames, and R. M. Weinshilboum
Primer on Medical Genomics Part XII: Pharmacogenomics--General Principles With Cancer as a Model
Mayo Clin. Proc., March 1, 2004; 79(3): 376 - 384.
[Abstract] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
E. L. Goode, C. M. Ulrich, and J. D. Potter
Polymorphisms in DNA Repair Genes and Associations with Cancer Risk
Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1513 - 1530.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.